{"title":"NICE recommends osimertinib for NSCLC within Cancer Drugs Fund","authors":"","doi":"10.1007/s40274-021-08267-7","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"97 6 1","pages":"36"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics & Outcomes News","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40274-021-08267-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
